The DOI matches its Crossref record.
Reversal of Anemia by Erythropoietin Therapy Retards the Progression of Chronic Renal Failure, Especially in Nondiabetic Patients
Abstract
Therapy with human recombinant erythropoietin (EPO) has been accepted as effective for renal anemia in dialysis patients. However, studies in rats have shown that correcting anemia with EPO may affect the progression of renal dysfunction. In humans, however, the effect of EPO on residual renal function is a matter of controversy. We, therefore, investigated whether the long-term administration of EPO to predialysis patients influences residual renal function. Anemic patients at the predialysis stage with a serum creatinine (Cr) concentration ranging from 2 to 4 (average 2.9) mg/dl and a hematocrit (Ht) of less than 30% were randomly assigned to two groups which consisted of anemic patients not treated with EPO (group I, untreated anemic controls, n = 31) and anemic patients treated with EPO (group II, treated anemics, n = 42). Patients with nonsevere or moderate anemia (Ht > 30%) with a Cr ranging from 2 to 4 (average 2.6) mg/dl were also recruited as nonanemic controls (group III, untreated nonanemic controls, n = 35). Blood pressure was controlled to the same degree among the three groups by combined treatment with calcium antagonists and angiotensin-converting enzyme inhibitors. All patients were kept strictly on a low-protein (0.6 g/kg/day) and a low-salt (7 g/day) diet. The degree of control of dietary protein and blood pressure and the frequency of angiotensin-converting enzyme inhibitor administration were comparable among the three groups. The primary end point for each patient was a doubling of the baseline Cr which yielded cumulative renal survival rates which were plotted against time. Ht rose significantly from 27.0+/-2.3 to 32.1+/-3.2% in group II (n = 42, p < 0.001) with a rate of increase of 0.4+/-0.06%/week. However, it declined from 27.9+/-1.8 to 25.3+/-1.9% in group I (n = 31, p < 0.001) and from 35.9+/-3.5 to 32.2+/-3.9% in group III (n = 35, p < 0.001). Cr doubled in 26 patients (84%) in group I as compared with 22 (52%) in group II and 21 (60%) in group III. The cumulative renal survival rates in groups II and III were significantly better than that in group I: p = 0.0003 (group I vs. group II) and p = 0.0024 (group I vs. group III). However, there was no difference in the renal survival rate between groups II and III (p = 0.3111). The better survival rate obtained in group II was attributable to the better survival rate for the nondiabetic patients in this group. The present study suggests that anemia, per se, is a factor in the progression of end-stage renal failure and that reversal of anemia by EPO can retard the progression of renal failure, especially in nondiabetic patients, provided that blood pressure control, rate of increase in Ht, and dietary protein restriction are appropriate.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Guralnik, J. M., Eisenstaedt, R. S., Ferrucci, L., Klein, H. G., & Woodman, R. C. (2004) · Blood · doi:10.1182/blood-2004-05-1812 · Cited by 1,450
Silverberg, D. S., Wexler, D., Blum, M., Keren, G., Sheps, D., Leibovitch, E., Brosh, D., Laniado, S., Schwartz, D., Yachnin, T., et al. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)00613-6 · Cited by 728
(2007) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2007.06.008 · Cited by 727
Jones, M., Ibels, L., Schenkel, B., & Zagari, M. (2004) · Kidney International · doi:10.1111/j.1523-1755.2004.00450.x · Cited by 665
Keane, W. F., Brenner, B. M., de Zeeuw, D., Grunfeld, J.-P., McGill, J., Mitch, W. E., Ribeiro, A. B., Shahinfar, S., Simpson, R. L., Snapinn, S. M., et al. (2003) · Kidney International · doi:10.1046/j.1523-1755.2003.00885.x · Cited by 539
Erythropoietin as a Retinal Angiogenic Factor in Proliferative Diabetic Retinopathy
Watanabe, D., Suzuma, K., Matsui, S., Kurimoto, M., Kiryu, J., Kita, M., Suzuma, I., Ohashi, H., Ojima, T., Murakami, T., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa041773 · Cited by 484
The prevalence of anemia in patients with chronic kidney disease
McClellan, W., Aronoff, S. L., Bolton, W. K., Hood, S., Lorber, D. L., Tang, K. L., Tse, T. F., Wasserman, B., & Leiserowitz, M. (2004) · Current Medical Research and Opinion · doi:10.1185/030079904x2763 · Cited by 474
How the Target Hemoglobin of Renal Anemia Should Be?
Mimura, I., Tanaka, T., & Nangaku, M. (2015) · Nephron · doi:10.1159/000440849 · Cited by 416
Gouva, C., Nikolopoulos, P., Ioannidis, J. P. A., & Siamopoulos, K. C. (2004) · Kidney International · doi:10.1111/j.1523-1755.2004.00797.x · Cited by 410
Meta-analysis: Erythropoiesis-Stimulating Agents in Patients With Chronic Kidney Disease
Palmer, S. C., Navaneethan, S. D., Craig, J. C., Johnson, D. W., Tonelli, M., Garg, A. X., Pellegrini, F., Ravani, P., Jardine, M., Perkovic, V., et al. (2010) · Annals of Internal Medicine · doi:10.7326/0003-4819-153-1-201007060-00252 · Cited by 363
NANGAKU, M. (2004) · Internal Medicine · doi:10.2169/internalmedicine.43.9 · Cited by 336
Japanese Clinical Practice Guideline for Diabetes 2016
Haneda, M., Noda, M., Origasa, H., Noto, H., Yabe, D., Fujita, Y., Goto, A., Kondo, T., & Araki, E. (2018) · Diabetology International · doi:10.1007/s13340-018-0345-3 · Cited by 319
Predicting initiation and progression of chronic kidney disease: Developing renal risk scores
Taal, M. W., & Brenner, B. M. (2006) · Kidney International · doi:10.1038/sj.ki.5001794 · Cited by 282
2008 Japanese Society for Dialysis Therapy: Guidelines for Renal Anemia in Chronic Kidney Disease
Tsubakihara, Y., Nishi, S., Akiba, T., Hirakata, H., Iseki, K., Kubota, M., Kuriyama, S., Komatsu, Y., Suzuki, M., Nakai, S., et al. (2010) · Therapeutic Apheresis and Dialysis · doi:10.1111/j.1744-9987.2010.00836.x · Cited by 278
What is so bad about a hemoglobin level of 12 to 13 g/dL for chronic kidney disease patients anyway?
Besarab, A., Frinak, S., & Yee, J. (2009) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2008.12.007 · Cited by 34
Metadata
- Authors
- Kuriyam, S., Tomonari, H., Yoshida, H., Hashimoto, T., Kawaguchi, Y., & Sakai, O.
- Venue
- Nephron
- Publisher
- S. Karger AG
- Published
- 1997
- Volume
- 77
- Issue
- 2
- Pages
- 176-185
- ISSN
- 1660-8151 (ISSN-L)
- 1423-0186
- 0028-2766
- OpenAlex
- W2067988311
- Cited by
- 374
- References
- 0
- FWCI
- 14.31
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.